Medtronic plc (mdt)
MDT — Company Overview
Investors tracking MDT follow a Medical Devices name listed on NYQ within Healthcare.
| Ticker | MDT |
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | NYQ |
| Market cap | $114.23B |
| Last price | $89.30 |
| Size category | Large Cap |
MDT — Business Description
The business profile of Medtronic plc (MDT) reflects its role in Medical Devices. Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories,…
Official website: https://www.medtronic.com.
MDT — Investment Thesis
Medtronic plc (MDT) attracts investors weighing Medical Devices fundamentals against current market pricing.
- Revenue is expanding at roughly 13.7% year-over-year (public data).
- Trailing P/E of 22.38× sits in a moderate band relative to high-growth peers.
- Forward P/E (13.94×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 3.2% adds an income component to total return.
- Equity market capitalization is approximately $114.23B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
MDT — Financial Health
MDT financial profile reflects operating efficiency and capital structure using available market fundamentals.
Profit margin near 13.9% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $5.41B supports balance-sheet flexibility.
| Trailing P/E | 22.38× |
| Forward P/E | 13.94× |
| Price / Sales | 3.04× |
| Price / Book | 2.28× |
| Gross margin | 65.3% |
| Operating margin | 19.3% |
| Profit margin | 13.9% |
| Return on equity | 10.6% |
| Debt / Equity | 55.37 |
| Free cash flow | $5.41B |
MDT — Growth Outlook
Growth outlook for Medtronic plc (MDT) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 13.7% indicates strong top-line momentum.
- Earnings growth of 40.7% year-over-year supports improving profitability.
- Price is 16.0% below the 52-week high.
- Shares trade 21.8% above the 52-week low — limited rebound so far.
MDT — Competitive Position
Medtronic plc (MDT) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Medical Devices.
- Market capitalization of $114.23B places MDT among large-cap peers.
- Gross margin near 65.3% may reflect pricing power or favorable mix.
MDT — Strengths
Strengths for Medtronic plc (MDT) inferred from public financial metrics:
- Revenue growth of 13.7% year-over-year.
- Earnings growth of 40.7% year-over-year.
- Gross margin of 65.3% supports competitive unit economics.
- Positive free cash flow ($5.41B).
- Dividend yield of 3.2% for income-oriented holders.
- Moderate leverage (debt/equity 55.37).
MDT — Weaknesses
Weaknesses and pressure points for Medtronic plc (MDT) based on available data:
Insufficient public data to assess this factor.
MDT — Opportunities
- Sustained revenue growth (13.7%) could support multiple expansion if margins hold.
- Trading 21.8% above the 52-week low — potential recovery if fundamentals stabilize.
- Dividend yield of 3.2% appeals to total-return investors.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
MDT — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
MDT — Summary
Medtronic plc (MDT) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $89.30 with market cap $114.23B. Trailing P/E 22.38×. Revenue grew 13.7% year-over-year per public data. Notable strengths include revenue growth of 13.7% year-over-year. Review free estimates and earnings pages for MDT; upgrade for institutional ownership and live headlines.
Start Free — open MDT in Vest Terminal
Access live data, filings, ownership, and analysis for Medtronic plc.
Medtronic plc FAQ
What does Medtronic plc (MDT) do?
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio…
What is MDT's P/E ratio?
Medtronic plc has a trailing P/E of 22.38× based on publicly available market data.
Does MDT pay a dividend?
Indicated dividend yield: 3.2%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MDT in?
Medtronic plc is classified in Healthcare (Medical Devices) on NYQ.
What is MDT's market capitalization?
Approximate market cap: $114.23B.
What are the main risks for MDT?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of MDT?
Potential positives include revenue growth of 13.7% year-over-year, earnings growth of 40.7% year-over-year.
Where can I get analyst estimates for MDT?
Public analyst price targets and consensus for Medtronic plc are on the free /stocks/mdt/estimates page. Deeper estimate history and models are available in Vest Terminal.